Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
23.27
+0.16 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
March 02, 2024
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 27, 2024
From
Exelixis, Inc.
Via
Business Wire
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
February 23, 2024
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
2 Stocks Under $30 to Buy and Hold
February 19, 2024
You don't need to be a millionaire to get started. Investing on a budget can work, too.
Via
The Motley Fool
The 3 Best Biotech Stocks to Buy in February 2024
February 13, 2024
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.
Via
InvestorPlace
Recap: Exelixis Q4 Earnings
February 06, 2024
Via
Benzinga
Earnings Scheduled For February 6, 2024
February 06, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.
Via
Benzinga
Earnings Preview For Exelixis
February 05, 2024
Via
Benzinga
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
February 05, 2024
NASDAQ:EXEL, a growth stock which is not overvalued.
Via
Chartmill
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
February 13, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
February 10, 2024
The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Breaking Down Exelixis: 7 Analysts Share Their Views
January 30, 2024
Via
Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
3 Attractive Medical Stocks To Buy After Earnings
February 08, 2024
Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare...
Via
Talk Markets
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
February 06, 2024
EXEL earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
February 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 01, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
January 25, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
January 23, 2024
From
Exelixis, Inc.
Via
Business Wire
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
Via
Benzinga
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
January 21, 2024
These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.
Via
InvestorPlace
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
January 18, 2024
From
Exelixis, Inc.
Via
Business Wire
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
January 18, 2024
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.
Via
InvestorPlace
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell'
January 12, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified
Via
Benzinga
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
January 11, 2024
Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced.
Via
Chartmill
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.